Navigation Links
EntreMed to Present at BioPartnering Europe Conference
Date:10/10/2008

ny developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models a
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
2. EntreMed Reports Second Quarter 2008 Financial Results
3. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
4. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
5. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
6. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
7. EntreMed Receives Nasdaq Deficiency Notice
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Announces 2008 Corporate and Clinical Program Priorities
10. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
11. EntreMed to Present at BIO CEO and Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 This webinar will focus on ... safety assessment in biosimilars. , Regulatory frameworks are evolving ... development, however the complex nature of biopharmaceuticals makes the ... efficacy extremely challenging. Based on the specific aspects of ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how ... latent viruses is the Epstein Barr Virus (EBV), and one ... is a chronic inflammatory disease that destroys the body’s joints. ... patients have high concentrations of EBV DNA in their bodies ...
(Date:1/15/2014)... 15, 2014 AudioNotch is the internet's ... for the treatment of tinnitus. Patients listen to sound ... over a period of weeks to months, their tinnitus volume ... two forms: Notched Music and Notched White Noise. Now, AudioNotch ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Corporation announced today the,release of two major upgrades ... a multilaser capability and the Beta release of ... field well beyond,conventional optical limitations. The Multilaser ... two additional lasers including a 405nm (violet) laser ...
... Nektar,Therapeutics (Nasdaq: NKTR ) today announced the appointment ... reports to Nektar President and,CEO Howard W. Robin, and ... management team. "With his strong understanding of healthcare ... team at Nektar," Robin said. "He brings,significant experience in ...
... 28% over the prior comparable period to A$44.4 ... comparable period to A$4.6 million -- Excluding ... period to A$2.5 million from A$2.0 million -- Reported NPAT ... comparable period including one-off items -- Ellex brand product ...
Cached Biology Technology:Amnis Announces the Release of Multiple Upgrades to the ImageStream(R) System 2Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer 2Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer 3Ellex FY2007 Year End Results 2Ellex FY2007 Year End Results 3
(Date:4/20/2014)... doctors have long known that people with Down syndrome ... (ALL) during childhood, they haven,t been able to explain ... investigators has uncovered a connection between the two conditions. ... journal Nature Genetics , the researchers track the ... in Down syndrome to the cellular havoc that occurs ...
(Date:4/18/2014)... world population predicted to reach 9 billion by ... that considers human-altered landscapes such as farmland, according ... habitat that supports it might be an increasingly ... three-quarters of the land surface is directly affected ... human-caused impacts such as climate change. But what ...
(Date:4/18/2014)... Asteroid and comet impacts can cause widespread ecological ... even global scales. But new research from Brown University ... ancient life at the time of an impact. , ... has found fragments of leaves and preserved organic compounds ... in Argentina. The material could provide a snapshot of ...
Breaking Biology News(10 mins):Dana-Farber researchers uncover link between Down syndrome and leukemia 2Dana-Farber researchers uncover link between Down syndrome and leukemia 3Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3
... Love," conducted by Syracuse University Professor Stephanie Ortigue, reveals ... same euphoric feeling as using cocaine, but also affects ... in love only takes about a fifth of a ... and an adjunct assistant professor of neurology, both in ...
... at LSU Health Sciences Center New Orleans has found that ... the hormone that regulates water retention in the body on ... for diseases like high blood pressure, congestive heart failure, and ... November 1, 2010 issue of Endocrinology . Daniel Kapusta, ...
... has created a Green Carbon Center to bring the benefits ... other energy sources together in a way that will not ... a means to recycle carbon dioxide into useful products. ... fact is humans are throwing away a potentially valuable resource ...
Cached Biology News:Falling in love 'more scientific than you think,' according to Syracuse University professor 2LSUHSC study IDs proteins regulating water retention in salt-sensitive hypertension 2Green Carbon Center takes all-inclusive view of energy 2Green Carbon Center takes all-inclusive view of energy 3
... cytochrome P450 (CYP450) metabolite postulated to play ... cerebral vasculature. In rat cerebral microvessels, 20-HETE ... vasoconstriction. 20-HETE is excreted mainly as the ... (20-40 pg/ml in human urine) is about ...
... are designed to rapidly and reliably amplify ... APA Technology. APAgene provides hassle-free, ready-to use ... necessary ingredients are provided in each kit. ... for gap filling, localized cloning of genomic ...
Mol wt: average mol wt16,951.27 Da by calculation...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
Biology Products: